A dramatic increase in obesity prevalence and cardiovascular morbidity is expected for the coming years. However, with relevance to the heart, little is known about the specific contribution of obesity on associated morbidity. Consequently, global analysis of gene regulations in human heart was undertaken to monitor molecular regulations related to obesity or to obesity-related hypertension. Transcriptome analysis using cDNA arrays was performed in right appendage biopsies from obese patients (n=5), from patients with arterial hypertension with (n=5) or without obesity (n=5), and from 5 leans. All biopsies came from patients that had cardiac surgery and coronary bypass. Statistical analysis of the data revealed 2686 differentially expressed genes out of 11,500 when compared with lean tissues. Differential expression was verified by real-time PCR in 84% of 50 randomly chosen genes. Among genes encountered, 397 were specifically regulated in obese, 1,299 in non-obese hypertensive, and 355 in obese hypertensive patients, respectively, whereas an additional set of 153 genes was differentially expressed in all these situations. Ontology analysis, hierarchical clustering, and molecular pathway analysis indicated that the heart molecular picture of obesity differs clearly from that observed for obesity-related hypertension or arterial hypertension. Clearly, the Wnt pathway known to be involved in cardiac hypertrophy mechanisms, showed opposite regulation in obese heart compared with hypertensive heart and potentially prevented the development of cardiac remodeling in obese patients. All over, this work shows that uncomplicated obesity has a strong impact on cardiac gene expression, which could be considered as precursor signs for future cardiac disease and also demonstrates that obesity-related hypertension generates a heartmolecular-distinct phenotype that cannot be predicted by a simple sum of the impact of obesity and arterial hypertension on gene expression.
besity is increasing to alarming levels around the world with at least 61% of the adults in United States considered overweight (1) . Based on prospective studies, ~400,000 deaths could be attributed to obesity each year in the United States (2) , mainly as consequences of heart diseases, including ischemic cardiopathies and heart failure (3). The mechanisms accounting for obesity-related morbidity include its tight association with arterial hypertension (4) and endocrine and metabolic disturbances such as diabetes mellitus (5) or dyslipidemia (6) .
The possibility that part of the cardiac complications is specifically due to obesity or increased fat mass and is independent from arterial hypertension or metabolic disturbances has not been extensively investigated despite that adipose tissue has been shown to secrete multiple adipocytokines of which some have been shown to participate in cardiovascular disorders such as leptine (7), angiotensinogen (8) , adiponectin (9) , TNF-α (10), or TGF-β (11) . Moreover, even if they are not specific for obesity, functional changes in the heart have been shown in healthy obese patients such as, for instance, a decrease in heart rate variability (12) , a change associated with increased risk of death in cardiac diseases (13, 14) and in the general population (15) .
We have recently reported data on early transcriptional regulation at the cardiac level obtained in dogs submitted for 9 weeks to a high-fat diet (16) and also shown that, in this model, changes in heart rate are related to a down-regulation of muscarinic receptors (17) . However, this experimental model does not allow us to distinguish between adaptations due to arterial hypertension and those specific to the development of fat mass. Moreover, these data only concern short-term adaptations; whereas in humans, obesity often lasts several decades before cardiac pathologies occur.
Therefore, we decided to investigate the heart transcriptome remodeling focusing on changes specifically related to obesity. DNA microarray transcriptome profiling has been proposed as a powerful tool to study cardiac molecular phenotypes, which allows a simultaneous analysis of expression of thousands of genes (18, 19) . It has been recently used to study human heart failure (20, 21) and congenital heart defects (22) as well as left ventricular hypertrophy in animals (23). In the present study, microarray analysis was performed on right auricle samples from noncomplicated obese patients. Comparison of the results with those obtained in patients with obesity-related hypertension or in non-obese hypertension patients was also performed in order to discriminate between changes specifically linked to obesity or to arterial hypertension.
MATERIAL AND METHODS

Patients and heart sampling
All patients included in the study gave their informed consent for sample collection and molecular analysis prior to their inclusion. Patients were carefully selected by the physicians from the Obesity Clinic of the Department of Cardiology, Toulouse University Hospital prior to cardiac surgery for coronary bypass due to coronary disease. Criteria for inclusion and group allocation were body mass index (BMI) and blood pressure (BP). Patients were excluded with an ejection fraction <45% when measured by echography or with diabetes mellitus. In addition, all medications taken by the patients were carefully recorded (data not shown). All participants underwent an interview; a physical examination, including New York Heart association (NYHA) class assessment; and a 6-min walking-test, fasting laboratory testing, chest X-ray, echocardiography, and 12 lead ECG. All patients were in NYHA class 2. In all patients, no difference was found in these parameters, which confirmed that ejection fraction was closely related with the functional condition of these patients. Mean walking distance was of 420 m and no difference was found between the four groups. Out of more than 150 patients, three groups of patients paired for age, sex, and drug regimen were selected (Table 1 ). The group of obese patients (Group O) comprised five patients (BMI > 30 kg/m 2 ) with normal blood pressure (BP < 140/90 mm Hg) and no history of arterial hypertension or of antihypertensive drug prescription. Two groups of hypertensive patients (BP > 140/90 mm Hg) at examination or taking antihypertensive medication were also formed: a group of obese hypertensive patients (group OH: BMI > 30 kg/m 2 , n=5) and a group of non-obese hypertensive patients (group H: BMI: BMI <25 kg/m 2 , n=5). The results in patients were compared with those of a lean group composed by five non-obese normotensive patients without heart failure or diabetes mellitus undergoing cardiac surgery because of coronary disease. The reasons for rejection included inadequate age and unclear medical history, concomitant to diseases susceptible to introduce biases (congestive heart failure, valvular disease, renal failure, infection, cancer). Samples from right auricle appendages were collected from the Department of Cardiovascular Surgery of Toulouse University Hospital at the beginning of cardiac surgery and were of extra corporeal circulation. Samples were immediately washed in cold buffer, snap-frozen in liquid nitrogen and maintained at -80°C until analysis. Non-used heart samples were destroyed.
RNA extractions and cDNA labeling
Total RNA was isolated from the myocardium by using TRIzol reagent (Invitrogen, France) as described by the manufacturer. RNA integrity was checked with an Agilent Bioanalyser apparatus. cDNA was synthesized from 1 µg of total RNA using Strip-EZ RT mRNA labeling kit (Ambion, Austin, TX) and α-[
33 P]-dATP (Amersham, Buckinghamshire, UK).
DNA array hybridization and expression analysis
Hybridization to the research genetics membranes GF200 and GF201 was performed in UltraArray Hyb buffer (Ambion). Washes and chemical stripping were performed as recommended by Ambion. Membranes were hybridized up to five times and a diagram was generated to ensure that each membrane was used equally for each group of patients. We did not observe signal losses after four chemical strippings. This observation is in accordance with Ambion's manual, which shows that up to 10 strippings are possible with this protocol. Membranes were exposed for ~24 h in a cassette and revealed with a Storm 860 PhosphorImager (Molecular Dynamics, Eugene, OR). Signal intensity was analyzed with X-dot reader software (COSE) and normalized to the mean intensity from all the measured values. Results displayed in Table 2 are shown as ratio of obese/lean (O vs L), obese hypertensive/lean (OH vs L) or hypertensive/lean (H vs L) of normalized data.
Real-time PCR control of differential expression
A set of 50 genes was randomly chosen for real-time PCR validation of the differential expression (24). Oligos were synthesized by Proligo Company and designed with Primer Express software (Table 3) . Real-time PCR was performed with the Sybrgreen master mix reagent (Applied Biosystems, Foster City, CA) in a GeneAmp 5700 apparatus. Standard curve method was used for relative quantification of the PCR products, and gene expressions were normalized to 18S RNA quantification. Real-time PCR was statistically analyzed with SigmaStat software.
Ontology clustering
Ontology clustering was performed with 2051 differentially expressed and known genes using Onto-Express Software (25).
Molecular regulation pathways analysis
GenMapp software (http://www.genmapp.org) was used to analyze and draw molecular pathways regulations.
Hierarchical clustering
Hierarchical clustering was performed on normalized X-dot reader dataset after SAM analysis with Cluster Software and drawn with TreeView software (26). The clustering was performed on the average linkage clustering method for the genes and the arrays. Once clusters generated, genes lists from each cluster were analyzed by Ontoexpress software for ontology searches. Genes with clear relevant ontology were listed in Table 4 .
Statistical analysis
All molecular studies were performed by investigators blind to the clinical status of the patients until the end of clustering. cDNA Array data were analyzed for statistical relevance with the use of SAM software (27). SAM is a permutation-based technique that permits the estimation of the false discovery rate (FDR) for set of genes. The FDR is similar to P-value in standard statistical testing but can accommodate the effects of non-normal distribution in the data and multiple testing. SAM gives a lambda value for each gene on an array, which describes how likely it is that the gene is expressed differently between the two sample populations. A large value of lambda means that the gene is almost certainly expressed differentially, whereas a small value (close to 0) indicates no evidence for differential expression. SAM was set up with a FDR <0.05.
RESULTS
Global analysis of differential expression
A differential expression of at least three times over the background of 2686 genes out of 11,500 was observed when compared with leans in the three patient groups. The results are depicted in Fig. 1 . DNA microarrays also revealed a set of 153 genes with non-specific differential regulation and similar changes in each of the three patients groups. Up to 153 genes, which were found to be differentially regulated in Group O, displayed identical regulation in Group OH. 291 genes were submitted to identical regulation in Groups O and OH. A limited number of 38 genes shared similar regulation within Groups O and H. Finally, a set of 397 genes was identified to have a differential regulation of expression and were specific to Group O. In the same way, 355 genes were found to be specifically regulated in Group OH and 1299 in Group H.
To validate the results of statistical analysis with SAM software, real-time PCR was performed on 50 randomly chosen genes identified with microarrays in each group as displaying a differential regulation in the range of 0.07 to 7.09 (i.e., 14-fold repression or sevenfold induction; Table 2 ). Out of the 50 primer couples tested, 6 failed to amplify the cDNA in Sybrgreen assays or generated several PCR products. Therefore, expression was checked for the remaining 44. A similar differential expression (up-or down-regulation) vs. leans for 41 genes out of these 44 tested (success rate 93%) with microarrays was observed using real-time PCR (range: 0.05 to 78; i.e., 20-fold repression or 78-fold induction) but the significance level was not reached for 7 genes. Therefore, one could consider a confirmation rate of 77% that is also a consequence of real-time PCR dynamics and variability and a rather low number of patients to reach statistical significance. In overall, a differential expression was validated by using the two methods for an average of 85% of the genes tested. Absence of PCR validation for 7 genes can be explained by false-positive or PCR artifacts. A larger dispersion in values due to a more dynamic sensitivity of real-time PCR may also be involved in small groups. We observed a much higher ratio by realtime PCR when compared with microarrays for endothelin 1, LDR-associated protein 1, adenosine A1 receptor, and Stomatomedin A. This phenomenon is quite common and has also been observed in a number of transcriptome studies [see for instance (28, 29)]. According to the symatlas (http://symatlas.gnf.org/SymAtlas/), some genes are expressed at a rather low or high level in heart. Therefore, we may have a more accurate measurement by real-time PCR that is a much more sensitive assay with a much broader range of measurement.
Ontology analysis
Ontology analysis was performed on each gene cluster from the clustering analysis followed by a global ontology analysis focusing on eight gene categories for each patient group. The results, which are depicted in Fig. 2 , show that from a qualitative point of view the profile of gene adaptation in hearts of patients from Group O is quite different from that observed in patients from OH and H groups. A larger percentage of genes involved in cell-cycle and developmental processes as well as in cell structure characterized by changes in the hearts from OH and H groups. Whereas, the changes in genes encoding secreted proteins, involved in inflammation, apoptosis, or the extra-cellular matrix were more represented in the hearts from Group O.
Hierarchical clustering analysis
The results of this analysis were performed on whole heart genes transcribed in hearts from patients and leans are depicted in Fig. 3 (see also supplementary materials for clusters close examination). Twelve clusters, numbered from 1 to 12, were identified. They are formed by groups of heart genes found to be co-regulated in each patient within each group. As indicated in the Materials and Methods section, clustering was performed by an experimental investigator blind to the clinical status of the patients.
From a global point of view, this analysis indicates dramatic changes in the pattern of expression in heart between leans and each patient group. In patients from Group O, specific up-regulation of clusters 2, 10, and 12 is observed. A number of clusters displayed similar regulation in both O and OH groups (overexpressed: cluster 11; repressed: clusters 1 and 5). The pattern of regulation in O and OH groups was clearly different from that observed in patients from Group H, even if some clusters shared the same regulation in both OH and H groups (clusters 3, 4, and 9).
Clustering analysis also shows that the pattern of heart gene expression in OH patients is not the result of additive effects of arterial hypertension and obesity. For instance, in Group OH, a strong overexpression of genes from clusters 6 and 8 is observed and contrasts with the repression of this set of genes in both O and H groups. A selection of genes of interest based on their ontology with differential regulation ascribed to obesity or obesity-dependent hypertension is depicted in Table 4 . An exhaustive list of differentially expressed genes in each patient group and bibliographic references for Table 4 can be found at the following web address: http://www.pharmacovigilance-toulouse.com.fr/publi2004PhExp.htm
Molecular regulation pathways analysis
GenMapp software displayed an opposite regulation of the Wnt pathway in heart from Hypertensive patients (up-regulated) vs heart from obese patients (down-regulated; Fig. 4 ).
Analysis of expression of a selection of genes known in cardiac contractions and in heart remodeling
We observed significant differential regulation for a set of genes that are well known for their importance in heart contraction, such as genes encoding for K + and Ca 2+ channels, Na + /K + transporter, ryanodine receptor, tropomyosin, and myosin. We also noticed differential regulation for gene-encoding proteins known to be involved in myocardium remodeling, such as endothelin, metalloproteinases 1 and 9, integrins, MEF, and GATA4 transcription factors (Table 5) .
DISCUSSION
This study was designed to investigate the transcriptome regulations specifically related to obesity or to obesity-related hypertension in human hearts by using DNA microarrays and functional genomics analysis. The main finding is that even in non-complicated obese subjects with no arterial hypertension or endocrine and metabolic disorders, strong adaptations occur in the heart at the molecular level. Moreover, this study also shows that expression profile related to obesity dramatically differs from that observed in obesity-related hypertension but also from that observed essentially in arterial hypertension. Analyses of gene function of differentially expressed genes in patients provide a number of possible molecular hypotheses to explain heart rate alterations and myocardium remodeling (Table 5) . Clearly, alteration in expression for ionic channels encoding gene can account for altered contractility. Expressions of integrins that are extracellular matrix receptors are known to couple mechanical stimuli to functional responses. Regulated expression of integrins is a fundamental process in cardiac remodeling (30, 31) that was observed in co-regulation with matrix proteinase 1 and 9 (Table 5 ). In addition to these extracellular matrix gene regulations, genes involved in cardiac development (MEF factors) or hypertrophy (endothelin) had an altered expression. These observations could explain the mechanisms that lead to heart hypertrophy observed in obese and hypertensive patients.
The first question rising from our results is the quality of the population studied. Because of evident reasons, analysis of heart samples was performed only on patients undergoing coronary bypass surgery and extra-corporeal circulation, and this explains why we have no "true" control group. However, because the reason for cardiac surgery was identical in leans and in patients groups, it can be considered that even if coronary disease may per se produce changes in the heart transcription profile, this factor probably would not influence the final results of the study. Apart from this point, we paid a lot of attention to selecting homogeneous groups of patients on a clinical basis, thus excluding patients with a decreased ejection fraction or diabetes mellitus. The quality of patient selection and the validity of genomic analysis appears thus to be correct. In fact, the individual variability in gene expression level within each group of subjects was quite low, as indicated by the hierarchical analysis (see Fig. 3 ). Previous work on heart failure (HF) showed that few genes are affected by age or sex (32). This latter work did not take into account hypertension nor obesity. In this present study, differences in sex or age of the patients had minor effects on this global expression pattern performed with obese or hypertensive patients. As an noticeable result, Samples 2 and 5 that are from female patients in group H were settled close to each other (Fig. 3) . Some gender effect cannot be excluded but were not displayed at this largescale analysis. This clustering analysis grouped correctly all the patients (O, OH, H, and L groups) without the intervention of the investigator who was blind to the clinical status of the subject. As expected, the group with most heterogeneity is the group of obese and hypertensive patients. This can be explained by several factors among which the interactions between effects of obesity and of arterial hypertension surely play an important role. Moreover, some part of the variability may also be due to possible differences in fat mass deposit repartition in visceral and abdominal territories. Once again, this variability appears acceptable since clustering software considered the patients from this group as sharing enough similarities in expression pattern to put them in the correct clinical group.
Another point is the relevance of the results obtained with a reduced number of patients and in samples from the right appendages of the heart to molecular adaptations linked to obesity. Concerning the limited number of patients, it has been shown that using similar strategies, relevant changes in gene expression in human hearts have been published (21) . Moreover, the clustering analysis has been designed to investigate transcription profile in limited surveys with a low number of patients (26). As discussed above, the first important factor in such an approach is the quality of patient characterization in order to build homogeneous groups and, to a lesser point, the number of patients included. The choice of right appendage biopsies was made because it is the only heart tissue easily available in humans. However, this choice may have some consequences on our results. In fact, it is well established that morphological and functional changes at the cardiac level during obesity differ from those observed in isolated arterial hypertension. For instance, increased heart rate and decreased heart rate variability are frequently found in obesity in the absence of left ventricular hypertrophy in humans and in experimental models (33). A volumetric overload, which is considered as explaining obesityrelated hypertension, has not always the same consequences on heart transcription profile in the right auricle and in left ventricular levels in dogs made obese and hypertensive by a high-fat diet (17, 16) . Thus, our data do not allow a conclusion on the putative transcriptome regulations in other myocardial chambers and specifically in the left ventricle. However, this limitation does not interfere with our main findings, which show that in normotensive obese patients without diabetes mellitus or heart failure, obesity per se is associated with specific regulation of heart gene expression and that this gene expression profile is strongly different from that observed in obesity-related hypertension or in essential arterial hypertension.
A similar conclusion comes from clustering analysis, which clearly indicates that the expression profile in obese patients largely differs from that observed in leans and in hypertensive obese or non-obese patients. This finding strongly suggests that in obese patients with no evidence for obesity-related cardiac complication, a relation exists between heart gene expression and adipose mass. This relation probably involves multiple adipose tissue secretions with a known effect on the heart but may also be due to the volumetric overload characteristic of obesity. Whatever the case, this observation also suggests that changes observed in obesity could represent a pathophysiological basis for the understanding of the mechanisms driving the development of obesity-related diseases. In fact, beyond the descriptive aspect and the identification of a specific profile of transcription in the heart from obese patients we could also identify global gene adaptations in terms of physiology or biochemistry. One very interesting example was the opposite change (Fig. 4A, B) in genes encoding proteins involved in the Wnt pathway in the heart from obese and hypertensive patients. The Wnt signaling pathway plays a major role in cardiac myogenesis (34), myocardial hypertrophy, and heart failure (35) through various mechanisms among which the inhibition of GSK-3β activity (35) and the subsequent stabilization of the β-catenin complex (36) are examples. This leads to β-catenin translocation to the nucleus where it participates in the transcription processes through interaction with a nuclear transcription factor member of the TCF family (37). As shown in Fig. 4 , obesity is characterized by an overexpression of SRP4, an endogenous antagonist of the Wnt proteins, and not only a repressor of Wnt receptors (FDZ6 and FDZ4) but also of Dsh3, a direct inhibitor of GSK-3β activity. These changes will favor β-catenin ubiquitination and degradation in proteasomes (38) and direct repression of several transcription factors that play a pivotal role in cardiac hypertrophy such as c-myc, GATA4, and MEF2B [for review see (39)]. Finally, the regulation of the Wnt/β-catenin pathway observed in the obese heart should potentially prevent the development of cardiac hypertrophy. The mechanisms driving this regulation remain to be elucidated but they could be, at least in part, linked to the volume overload observed in obesity-related hypertension. In fact, it was recently shown that in rabbits, volume overloading induced by arteriovenous shunt provoked a decrease in expression of β-catenin and connexin 43 (40). By contrast, to what is observed in obese hearts, the changes identified in hearts from hypertensive patients (Fig. 4) are consistent with decreased GSK-3β activity, nuclear accumulation of β-catenin, and finally myocardial hypertrophy.
This work has several limitations apart from those discussed above. First, it does not give any information on the changes in specific cell types and thus further studies on separated cardiomyocytes or fibroblasts are required to define what kind of cardiac cells are most sensitive to the influence of obesity. Second, even if changes in gene expression were screened in order to eliminate non-significant variations, we did not verify whether they were associated with changes in protein expression or activity. Hence, the putative physiological significance of the regulation of the Wnt pathway in terms of heart remodeling remains to be confirmed by other specific studies. In addition, Wnt pathway regulation in heart from obese patients could be, at least in part, a consequence of adipokine secretions from adipose tissue. Identification of the adipokines implicated in the regulation of the synthesis of the Wnt pathway members could be of major importance in the investigation of the mechanisms that protect heart from remodeling.
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